SCHEDULE Filed 2025-02-03 Event 2025-02-03 SEC 0001104659-25-008666 →

Nantahala Capital Management, LLC → Evoke Pharma Inc

Stake: 15.99% Shares: 254,639 CUSIP: 30049G203 Class: Common Stock, par value $0.0001 per share

Item 4 — Purpose of Transaction

Item 4 is hereby supplemented by the addition of the following disclosure: The Reporting Persons have begun discussions with the Issuer regarding the selection of a second designee to the Issuer's board of directors pursuant to the September 2024 Letter Agreement. Upon appointment of the Reporting Persons' designee to the Issuer's board of directors, the Issuer will be required to disclose certain information concerning the designee in a Current Report filed with the SEC on Form 8-K.

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

1 13D/G filings on this issuer

0 other filings besides this one

Filer Track Record

1 filings by this filer

0 other filings in the data moat

Short Interest

—

Not in latest FINRA snapshot

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →